Long-term effectiveness, safety, and tolerability of doravirine in antiretroviral-experienced people with HIV in real life
Microbiology Spectrum · 2024
DOI: 10.1128/spectrum.00654-24 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Microbiology Spectrum, 2024. Verfasst von Marta Mejías-Trueba und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, University Hospital Virgen del Rocío, Seville, Spain. Hauptthemen laut MEDLINE: HIV Infections, Pyridones, Lamivudine, Anti-HIV Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MEC | Instituto de Salud Carlos III (ISCIII).
Abstract (Originalsprache)
Real-life data on doravirine (DOR) in different drug combinations are limited. We evaluated the effectiveness of DOR plus two nucleos(t)ide reverse transcriptase inhibitors (NRTI), mainly abacavir/lamivudine, and dual therapies in people with HIV (PWH), mostly virologically suppressed. Ambispective observational study that enrolled adults PWH who initiated a DOR-based regimen from September 2020 to February 2022 at a referral center in Spain. Participants were grouped as follows: A, received DOR plus two NRTI; B, dual therapy (DT) with DOR plus dolutegravir (DTG) or darunavir/cobicistat (DRVc); C, DOR plus ≥two antiretroviral drugs. The primary endpoints were treatment effectiveness at week 48 by intention-to-treat (ITT) and per-protocol analysis (OT). A cohort of 187 participants, 91% virologically suppressed, were analyzed after a median follow-up of 112 weeks (80–136). Group A received DOR plus abacavir/lamivudine (ABV/3TC) ( n = 109) or tenofovir/emtricitabine (TFV/3TC) ( n = 45). At week 48, the effectiveness of DOR plus ABV/3TC by ITT was 90.8% (CI 95 , 88.0–93.6), better than with TFV/FTC [73.3% (66.7–79.9); P = 0.003]. Only one virologic failure was observed. Mild adverse effects were the cause of treatment discontinuation in 7.8%, followed by switching to a single-tablet regimen. In group B, the effectiveness by ITT was 92.9% (CI 95 , 88.0–97.8) at week 48. No adverse effects or virologic failure were registered in this group. DOR plus two NRTI or DT have long-term effectiveness and safety as a switching option for PWH, mostly virologically suppressed. The DOR plus ABV/3TC combination has shown even better effectiveness than TFV/FTC. IMPORTANCE DOR-based regimens have shown long-term effectiveness and safety in PWH, mostly virologically suppressed. The combination of DOR plus ABV/3TC has shown even better safety and effectiveness than TFV/FTC. DOR plus two NRTI offers cost benefits compared to other regimens.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, University Hospital Virgen del Rocío, Seville, Spain.
- Infectious Diseases and Microbiology Clinical Unit. Instituto de Biomedicina de Sevilla/University Hospital Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain.
- Primary Care Pharmacist Service, Sevilla Primary Care District, Sevilla, Spain.
ORCID-Profile: Marta Mejías-Trueba, Luis F Lopez-Cortes
Förderung
- MEC | Instituto de Salud Carlos III (ISCIII)
Zitieren
APA
Mejías-Trueba, M., Gutierrez-Valencia, A., Llaves-Flores, S., Roca-Oporto, C., Herrero, M., Sotomayor de la Piedra, C., Lopez-Cortes, L. F., & Espinosa, N. (2024). Long-term effectiveness, safety, and tolerability of doravirine in antiretroviral-experienced people with HIV in real life. Microbiology Spectrum. https://doi.org/10.1128/spectrum.00654-24
Vancouver
Mejías-Trueba M, Gutierrez-Valencia A, Llaves-Flores S, Roca-Oporto C, Herrero M, Sotomayor de la Piedra C, et al. Long-term effectiveness, safety, and tolerability of doravirine in antiretroviral-experienced people with HIV in real life. Microbiology Spectrum. 2024. doi:10.1128/spectrum.00654-24
BibTeX
@article{MejasTrueba2024,
author = {Mejías-Trueba, Marta and Gutierrez-Valencia, Alicia and Llaves-Flores, Silvia and Roca-Oporto, Cristina and Herrero, Marta and Sotomayor de la Piedra, César and Lopez-Cortes, Luis F and Espinosa, Nuria},
title = {Long-term effectiveness, safety, and tolerability of doravirine in antiretroviral-experienced people with HIV in real life},
journal = {Microbiology Spectrum},
year = {2024},
doi = {10.1128/spectrum.00654-24}
}
EUVIMED